Download Free Critical Analysis Of Monoclonal Antibody Therapy In Transplantation Book in PDF and EPUB Free Download. You can read online Critical Analysis Of Monoclonal Antibody Therapy In Transplantation and write the review.

Critical Analysis of Monoclonal Antibody Therapy in Transplantation provides a critical analysis of monoclonal antibody therapies in transplantation. The book presents diverse approaches to monoclonal antibody therapy in transplantation and addresses some of the serious obstacles that remain both in understanding these mechanisms and in successfully applying them in clinical situations. The background and rationale for OKT3 therapy are examined and an extensive clinical experience with OKT3 induction therapy in cardiac transplantation is reviewed. The book also examines the background and rationale for the use of anti-TcR (??), anti-IL-2R, and anti-LFA-1 monoclonal antibodies in clinical transplantations. Other topics include the use of monclonal antibodies to CD4 and CD8 for the induction of adult transplantation tolerance in rodents and the possibilities for applying anti-idiotypical strategies that have proven useful in autoimmunity models to transplant recipients. Researchers and basic scientists involved in this field will find the book a fascinating and useful resource for their investigations.
Immunological Concepts in Transfusion Medicine provides a thorough discussion of the immune aspects of blood component transfusion, with in-depth information on the intricacies of immune responses to blood components and the immune processes that may be initiated in response to blood exposure. Written to increase knowledge and awareness of immune challenges such as alloimmunization and transfusion-related acute lung injury, this title bridges current basic scientific discoveries and the potential effects seen in blood recipients. - Complies the knowledge and expertise of Dr. Robert Maitta, an expert in immune responses and antibody function/structure studies. - Helps clinicians in the daily practice of caring for patients in need of transfusion support, as well as physicians in training when considering utilizing blood transfusions in a limited scope or in the setting of massive transfusion. - Includes an immunology primer as an introduction to in-depth chapters covering allergic immune reactions to blood components, transfusion-related immunomodulation, fetal and neonatal alloimmune thrombocytopenia and neonatal neuthropenia, complications of haploidentical and mismatched HSC transplantation, chimeric antibody receptor therapies, and much more. - Consolidates today's available information on this timely topic into a single, convenient resource.
Genic constructs. Five articles are devoted to this topic ranging from the B-cell function in transgenic animals to the various effects on diabetes complications. The section on NIDDM, comprising of 10 articles, deals both with new and existing models, their particular widely varying pathogenesis, genetic character istics and complications. The animals reviewed include: spontaneously diabetic OLETF rats, Chinese hamsters, Goto-Kakizaki rats, db/db mice, rhesus monkeys, dogs and an article demonstrating the genetic link between the Zucker fa/fa and corpulent cp/cp obese interstrains. We wish to welcome the new members to our Editorial Board, Dr. Hubert Kolb from Dusseldorf, Dr. Alex Rabinovitch from Edmonton, Dr. Takayoshi Toyota from Sendai and Dr. Soroku Yagihashi from Hirosaki. At the same time we would like to thank Dr. Douglas L. Coleman from Bar Harbor and Dr. George Eisenbarth from Denver for their editorial contribution to the previous LAD Vol umes who have retired from the Editorial Board. With great sadness we have to mention Dr. Otho Michaelis IV from Beltsville, MD who suddenly passed away this year. Otho, or Mike as he was called by friends, made a significant contribution in developing and metabolically defin ing several strains of corpulent cp rats and was extremely helpful in the editor ial work of the LAD series. His contribution will remain in a lasting memory of all researchers of animal diabetes.
Recent concern about the adverse effects and relative risks of anti- inflammatory therapies has been such that another meeting was organized in the highly successful series of meetings on this topic. Adverse effects of anti-rheumatic and anti-inflammatory drugs are of major concern to all involved in the prescription, care and management of rheumatic and other patients receiving these important drugs. The IVth International Meeting on Side-Effects of Anti-Inflammatory Drugs, held in Sheffield, UK, 7-9 August 1995, afforded a unique opportunity to hear the latest information and views on issues concerning the development of adverse effects from these drugs, the management of these effects, and the development of safer therapies. In addition to discussions on the safety relative to efficacy of established non-steroidal and steroidal anti-inflammatory drugs and disease-modifying agents, there was detailed consideration of the novel cyclo-oxygenase-2 selective NSAIDs which have recently been developed and introduced to the clinic. Also, the side effects from therapy with biologics, notably monoclonal antibodies and oral tolerance therapies, were considered. Among the other highlights in the programme were: Clinico-epidemiological studies on the adverse effects relative to use/efficacy of established and new anti-rheumatic drugs. Procedures for reducing the gastrointestinal adverse effects. Mechanisms and clinical significance of adverse effects in the gastrointestinal tract, liver, kidney, articular joints, skin and other organs from NSAIDs. Clinical status and mechanisms of action of the newer (third generation) of NSAIDs (e.g. etodolac, nabumetone, meloxicam). Medico-legal aspects of adverse effects from anti-rheumatic drugs. The concept of `conditional pharmacology' or the disease-dependence of the toxicological and pharmacological activity of the anti-inflammatory drugs. The papers in this book were selected from those presented at the meeting.
Provides a detailed survey of therapies for autoimmune diseases, exploring the rationale for their use and clinical data regarding their potential benefit.
First multi-year cumulation covers six years: 1965-70.
This long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety of the many and diverse therapeutic agents presented in a total of 13 chapters. It is predicted that by 2016, biologics will make up half of the world's 20 top-selling drugs and by 2018, biologic medicine sales will account for almost half of the world's 100 biggest selling drugs. Recombinant proteins dominate the growing list of the more than 200 approved biotherapeutic agents with targeted antibodies, fusion proteins and receptors; cytokines; hormones; enzymes; proteins involved in blood-clotting, homeostasis and thrombosis; vaccines; botulinum neurotoxins; and, more recently, biosimilar preparations, comprising the majority of approved biologics. Written with clinicians, other health care professionals, and researchers in mind, Safety of Biologics Therapy examines, in a single volume, the full range of issues surrounding the safety of approved biologic therapies. A good understanding of the risks and safety issues of modern biologics therapy is increasingly being demanded of all those connected with their development, handling, prescribing, administration and subsequent patient management. In addition to being of great value to clinicians in all branches of medicine, and to nurses, pharmacists and researchers, this book will prove invaluable for students taking undergraduate and graduate courses in the above disciplines and in the biomedical sciences.
This specially commissioned text covers a range of topics relating to chemotherapy and the immune system.